Changes of retinal morphofunctional parameters after submacular hemorrhage surgery
Year: 2021, volume 17 Issue: №2 Pages: 388-392
Heading: Тhematic supplement Article type: Original article
Authors: Fayzrakhmanov R.R., Bosov E.D., Shishkin M.M., Sukhanova A.V.
Organization: National Medical and Surgical Center n. a. N. I. Pirogov
Heading: Тhematic supplement Article type: Original article
Authors: Fayzrakhmanov R.R., Bosov E.D., Shishkin M.M., Sukhanova A.V.
Organization: National Medical and Surgical Center n. a. N. I. Pirogov
Summary:
Purpose: to evaluate by microperimetry and ОСТ the morphofunctional parameters of the retina during recombinant prourokinase subretinal introduction followed by pneumodislocation in comparison with anti-VEGF therapy in the long term for patients with submacular hemorrhage. Material and Methods. Depending on the surgical treatment choice, patients were divided into two groups. In the 1st group 11 patients (11 eyes) received anti-VEGF therapy; in the 2nd group 9 patients (9 eyes) underwent standard 25G vitrectomy with subretinal injection of 0.2-0.3 ml of prourokinase solution and airtamponade of 70% of the vitreous volume and introduction of anti-VEGF drugs 14 days afterthe operation. Results. In patients of the 2nd group, successful dislocation of the clot was achieved in 89% of cases; depression of the central retinal thickness was revealed by 4 times; the height of chorioidal neovascularization decreased by 2.8 times based on an improvement in visual functions by 10 times; the number of loci corresponding to areas of absolute scotoma decreased by 4.7 times, while the general photosensitivity of the retina increased by 12.6. Conclusion. The assessment of the retinal morphofunctional parameters demonstrates an increase in visual acuity due to favorable anatomical outcome and the subsequent maintenance of the achieved parameters in the long term in patients with submacular hemorrhage after subretinal injection of prourokinase and pneumodislocation followed by anti-VEGF therapy.
Bibliography:
1. Jonas JB, Cheung CMG, Panda-Jonas S. Updates on the Epidemiology of Age-Related Macular Degeneration. Asia Рас J Ophthalmol (Phila) 2017 Nov-Dec; 6 (6): 493-7. URL: https:// doi.org/10.22608/apo. 2017251
2. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014. URL: https://doi.Org/10.1016/s2214-109x (13) 70145-1
3. Gopinath B, LiewG, Burlutsky G, etal. Age-related macular degeneration and 5-year incidence of impaired activities of daily living. Maturitas2014; 77: 263-6. URL: https://doi.Org/10.1016/j. maturitas. 2013.12.001
4. Fayzrakhmanov RR, Shishkin MM, Bosov ED, et al. Pathomorphology of submacular hemorrhage (review). Saratov Journal of Medical Scientific Research 2021; 17 (1): 28-32.
5. Stanescu-Segall D, Balta F, Jackson TL. Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature. Surv Ophthalmol 2016 Jan-Feb; 61 (1): 18-32. URL: https://doi.Org/10.1016/j. survophthal. 2015.04.004
6. Fayzrakhmanov RR, Larina EA, Pavlovskiy OA. Microperimetry as a tool to assess retinal functional parameters in patients with recurrent macular hole. Russian Journal of Clinical Ophthalmology 2020; 20 (2): 51-5.
7. Ovchinnikova AD, Mironov AV, Dulgieru TO. The surgical treatment of massive submacular hemorrhages aggravating
the course of exudative form of AMD with automated subretinal injection. Fyodorov Journal of Ophthalmic Surgery 2020; 4: 43-9.
8. Jeong S, Park DG, Sagong M. Management of a Submacular Hemorrhage Secondary to Age-Related Macular Degeneration: A Comparison of Three Treatment Modalities. J Clin Med 2020 Sep 24; 9 (10): 3088. URL: https://doi.org/10.3390/jcm9103088
9. Fayzrakhmanov RR. Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice. Russian Ophthalmological Journal 2019; 12 (2): 97-105.URL: https://doi.org/10.21516/2072-007 6-2019-12-2-97-105.
10. Fayzrakhmanov RR. Anti-VEGF dosing regimen for neovascular age-related macular degeneration treatment. The Russian Annals of Ophthalmology 2018; (6): 105-13. URL: https://doi.org/10.17116/oftalma2018134061107.
11. Lincoff Н, Kreissig I, Stopa M, et al. A 40 degrees gaze down position for pneumatic displacement of submacular hemorrhage: clinical application and results. Retina 2008 Jan; 28 (1): 56-9. URL: https://doi.org/10.1097/iae. 0b013e31806e60db
12. Treumer F, Wienand S, Purtskhvanidze K, et al. The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPAand anti-VEGF. GraefesArch Clin Exp Ophthalmol 2017 Jun; 255 (6): 1115-23. URL: https://doi.org/10.1007/s00417-01 7-3620-2
13. Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res 2016 Jan; 50: 1-24. URL: https://doi.Org/10.1016/j. preteyeres. 2015.07.007
| Attachment | Size |
|---|---|
| 2021_02-1_388-392.pdf | 342.93 KB |
Русский
English